The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial

Clinical Infectious Diseases

Volumn 55, Issue 8, 2012, Pages 1080-1087

  Park, Wan Beom ^a   Kim, Nak Hyun ^a   Kim, Kye Hyung ^a   Lee, Seung Hwan ^a   Nam, Won Seok ^a   Yoon, Seo Hyun ^a   Song, Kyoung Ho ^a   Choe, Pyoeng Gyun ^a   Kim, Nam Joong ^a   Jang, In Jin ^a   Oh, Myoung Don ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ADULT; ADVERSE OUTCOME; AGITATION; ASPERGILLUS; CANDIDA; CONFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HALLUCINATION; HUMAN; HYPHOMYCETES; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPERGILLOSIS; CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIAZOLES;

EID: 84866665422     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis599     Document Type: Review

References (24)

1. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
2. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39:1241-4.
3. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008; 47:e7-10.
4. Levin MD, den Hollander JG, van der HB, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007; 60:1104-7.
5. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11.
6. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16:927-33.
7. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-5.
8. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55:4782-8.
9. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53: 1793-6.
10. Ascioglu S, Rex JH, de PB, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
11. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30:403-11.
12. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2011; 52:195-203.
13. National Cancer Institute. Common terminology criteria for adverse events: National Cancer Institute online guidelines 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 6 June 2012.
14. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
15. den Hollander JG, van AC, Rijnders BJ, Lugtenburg PJ, de MS, Levin MD. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006; 57:1248-50.
16. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89:592-9.
17. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34:91-4.
18. Shimizu T, Ochiai H, Asell F, et al. Bioinformatics research on interracial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18:48-70.
19. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-2.
20. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-13.
21. Kim KH, Lee S, Lee S, et al. Voriconazole-associated severe hyponatremia. Med Mycol 2012; 50:103-5.
22. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.
23. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56(Suppl 1):10-6.
24. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.